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Denise M. Oliansky,1 Richard A. Larson,2 Daniel Weisdorf,3 Hildy Dillon,4
Thomas A. Ratko,5 Donna Wall,6 Philip L. McCarthy, Jr.,1 Theresa Hahn1Clinical research published since the first evidence-based review on the role of hematopoietic stem cell
transplantation (SCT) in the treatment of acute lymphoblastic leukemia (ALL) in adults is presented and
critically evaluated in this update. Treatment recommendations changed or modified based on new evidence
include: (1) myeloablative allogeneic SCT is an appropriate treatment for adult (\35 years) ALL in first
complete remission for all disease risk groups; and (2) reduced-intensity conditioning may produce similar
outcomes to myeloablative regimens. Treatment recommendations unchanged or strengthened by new
evidence include: (1) allogeneic SCT is recommended over chemotherapy for ALL in second complete
remission or greater; (2) allogeneic is superior to autologous SCT; and (3) there are similar survival out-
comes after related and unrelated allogeneic SCT. New treatment recommendations based on new evidence
include: (1) in the absence of a suitable allogeneic donor, autologous SCT may be an appropriate therapy, but
results in a high relapse rate; (2) it is appropriate to consider cord blood transplantation for patients with no
HLAwell-matched donor; and (3) imatinib therapy before and/or after SCT (for Ph1 ALL) yields significantly
superior survival outcomes. Areas of needed research in the treatment of adult ALL with SCTwere identified
and presented in the review.
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In 1999, the American Society for Blood and
Marrow Transplantation (ASBMT) began the devel-
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6/j.bbmt.2011.07.019ASBMT EBR Steering Committee determined that
previously published reviews should be updated regu-
larly at approximately 5-year intervals. This consti-
tutes the first update of the adult acute lymphoblastic
leukemia (ALL) EBR originally published in 2006.UPDATE OF THE ADULTALL EBR
This adult ALL EBR update adheres to the meth-
odology and grading systems presented in Appendix A
(online only). In the original adult ALL EBR [1], each
article was summarized in detail in the text, accompa-
nied by summary tables comparing study designs and
patient outcomes. To streamline this update, a concise
summary of outcomes is provided in each section of
text, whereas descriptions of the study design, patient
population, and clinical outcomes of each article are
presented in detailed summary tables.
Evidence in each section is presented with the
highest quality studies first; studies of equal quality
are presented in descending order by study population
size. New evidence is provided first in each table,
followed by the highest quality studies (ratings 111
Biol Blood Marrow Transplant 18:18-36, 2012 19The Role of Cytotoxic Therapy with Hematopoietic SCT
in the Treatment of ALLand 211) used to make treatment recommendations
in the original adult ALL EBR. Both Level 1 and
Level 2 evidence is presented in the tables for each
study that provided biologic assignment (donor versus
no donor) and randomized (autologous SCT versus
chemotherapy) results.TREATMENT RECOMMENDATIONS
Table 1 contains the summary of consensus treat-
ment recommendations made by the expert panel
based on the summarized evidence on the use of
SCT to treat adult ALL. The consensus process is de-
tailed in Appendix A (online only) and involves a tele-
conference during which panelists critically discuss the
evidence for each section of the review and develop
treatment recommendations rated according to the
categories in Table 1 and in Appendix A, Table 2.
Table 1 presents new treatment recommendations
based on the adult ALL evidence published since
January 2005. In addition, the treatment recommenda-
tions from the original adult ALL EBR are incorpo-
rated into the respective tables when applicable. It is
indicated whether the new evidence strengthens, mod-
ifies, or does not change the original recommendation.
Four treatment options included in the original adult
ALL EBR treatment recommendations table were
removed in this update for the following reasons. First,
there were no new studies of purged or unpurged
autologous SCT, which is no longer relevant based
on current treatment preferences. In addition, non-
comparative studies of related and unrelated allogeneic
SCT were included in the original adult ALL EBR
because there were no comparative studies of these
techniques; however, in this update, comparative evi-
dence is presented, making these separate categories
unnecessary. Additional evolution of SCT techniques,
including advances in donor selection through high-
resolutionHLA typing andmatching and in supportive
care, all influence the current findings and limit their
direct comparability to earlier reports.TRANSPLANTATION VERSUS
CHEMOTHERAPY FOR ADULTALL
There were 11 studies published since the original
adult ALL EBR, and briefly summarized below, which
compared the efficacy of transplantation versus chemo-
therapy as treatment for adult ($18 years) patients with
ALL in first complete remission (CR1). Table 2 pres-
ents a detailed summary of the study designs, patient
populations, and outcomes from this new evidence.
Six high-quality (111 to 211) studies comparing
transplantation versus chemotherapy in CR1 that
were used to make treatment recommendations in the
original adult ALL EBR are also presented in Table 2.Table 3 presents two studies published since
January 2005 that compared transplantation versus
chemotherapy as treatment for relapsed or refractory
adult ALL. The quality ratings for these two studies
were 211 and 21. There were no studies in the orig-
inal adult ALL EBR that compared transplantation
versus chemotherapy for refractory or relapsed ALL,
or for ALL in second complete remission (CR2).Transplantation versus Chemotherapy for Adult
ALL in CR1
The 11 new studies presented in Table 2 provided
15 analyses, including four meta-analyses, four ran-
domized autologous SCT versus chemotherapy, four
donor versus no donor, and three allogeneic SCT ver-
sus chemotherapy6 imatinib for the treatment of adult
ALL in CR1. The quality ratings of these studies
ranged from 111 to 21.
Meta-analyses
To briefly summarize, in a meta-analysis of aggre-
gate data from 13 studies, Ram et al. [2] reported a sig-
nificant reduction in all-cause mortality in favor of
adult ALL patients in CR1 who underwent an alloge-
neic SCT versus chemotherapy alone or an autologous
SCT in studies which analyzed data by intention to
treat. In a meta-analysis of individual patient data
from four studies, Orsi et al. [3] reported a significant
difference in event-free survival (EFS) in favor of
ALL patients in CR1 who had a donor versus those
with no donor. Similarly, in a meta-analysis of aggre-
gate data from seven studies, Yanada et al. [4] reported
a significant advantage in overall survival (OS) for those
patients with a donor versus those with no donor. In a
meta-analysis of individual patient data from three
studies,Dhedin et al. [5] found no significant difference
in 10-year disease-free survival (DFS) or OS between
ALL patients in CR1 who underwent autologous
SCT versus those who received chemotherapy alone.
Autologous SCT versus Chemotherapy
In a prospective, multicenter study (UKALL XII/
ECOG 2993) by Goldstone et al. [6], 456 patients
were randomized to receive an autologous SCT or
chemotherapy alone. A significant difference in
5-year EFS and OS was reported in favor of chemo-
therapy for standard or high-risk patients. Marks
et al. [7] analyzed a subset of T-lineage ALL patients
from the UKALL XII/ECOG 2993 trial and found
no significant difference in 5-year OS between those
randomized to autologous SCT versus chemotherapy
alone. Ribera et al. [8] found no significant difference
in 5-year DFS or OS between high-risk ALL patients
in CR1 randomized to autologous SCT versus che-
motherapy alone. Similarly, Hunault et al. [9] found
no significant difference in 7-year relapse-free
Table 1. Summary of Updated Treatment Recommendations for Adult ALL
Indication for SCT Original vs. New Rec
Tx Rec
Grade*
Highest Level
of Evidence
†
Ref. No.
‡
Treatment Recommendation Comments
TRANSPLANTATION VS. CHEMOTHERAPY
Allogeneic SCT vs. chemotherapy
for ALL in first complete
remission
New evidence changed original
recommendation
A 1++ 2, 3, 5 (Table 2) Myeloablative allogeneic SCT is an appropriate treatment for adult ALL in CR1 for all disease risk
groups. Allogeneic SCT provides a significant improvement in overall and leukemia-free survival
in younger (<35 years), standard risk, Ph-negative ALL patients compared with less intensive
chemotherapy regimens. In older (>35 years), standard risk, Ph-negative ALL patients, a higher
TRM diminishes the significant survival advantage with allogeneic SCT.
Autologous SCT vs. chemotherapy
for ALL in first complete
remission
New recommendation based
on new evidence
A 1++ 2, 5 (Table 2) In the absence of a suitable allogeneic donor, autologous SCTmay be an appropriate therapy due to
similar survival outcomes and a shorter treatment duration when compared to chemotherapy
alone, but results in a high relapse rate. Maintenance therapy, biologic therapy, or tyrosine kinase
inhibitors may improve outcomes in selected patients, but these approaches need further study.
Allogeneic SCT vs. chemotherapy
for ALL in $CR2
New evidence strengthened
original recommendation
B 2++ 20 (Table 3) Allogeneic SCT is recommended over chemotherapy for ALL in CR2 or greater.
TRANSPLANTATION TECHNIQUES
Allogeneic vs. autologous SCT New evidence did not change
original recommendation
B 2++ 22 (Table 4) There is a preponderance of evidence favoring allogeneic over autologous SCT. There are
insufficient data to determine if this effect is more apparent in disease risk subgroups, including
Ph+ ALL.
Related vs. unrelated
allogeneic SCT
New evidence strengthened
original recommendation
B 2++ 28, 29 (Table 5) There are similar, and possibly equivalent, survival outcomes after related and unrelated allogeneic
SCT. Post-SCT complications may differ.
Unrelated donor BM vs. cord
blood SCT
New recommendation based
on new data published
since the original review
B 2++ 34 (Table 6) It is appropriate to consider cord blood transplantation for patients with no HLA-well-matched
donor option or those needing an urgent transplant.
Imatinib vs. no imatinib therapy
pre- and/or post-SCT
in Ph-positive ALL
New recommendation based
on new data published
since the original review
B 2++ 36, 37 (Table 6) Available data suggest imatinib therapy before and/or after SCT yields significantly superior
outcomes in OS and LFS. Ongoing studies using other tyrosine kinase inhibitors may enhance
this recommendation.
Comparison of induction
therapies before SCT
No treatment recommendation
based on new data published
since the original review
1++ 40 (Table 6) There are insufficient data to make a treatment recommendation regarding the benefit of any one
induction regimen.
Comparison of SCT
conditioning regimens
New evidence modified original
recommendation
B 2++ 42 (Table 6) There are not enough data to make a recommendation regarding the superiority of any one
conditioning regimen. There appears to be a benefit to TBI-containing regimens compared to
non-TBI-containing regimens.
Reduced intensity conditioning may produce similar outcomes to myeloablative regimens, but
available data are limited, thus reduced intensity regimens are appropriate only for patients with
ALL in remission who are unsuited for myeloablative conditioning.
ALL indicates acute lymphoblastic leukemia; SCT, stem cell transplantation; LFS, leukemia-free survival; CR, complete remission; BM, bone marrow; TRM, treatment-related mortality; OS, overall survival; TBI,
total-body irradiation.
*Definitions forGradeofRecommendation (seeAppendixA,Table 2):A5 at least 1meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++, anddirectly applicable to the target population; or
a systematic reviewofRCTsor abodyof evidenceconsistingprincipallyof studies rated as 1+, directly applicable to the target population, anddemonstratingoverall consistencyof results; B5Abodyof evidence including studies
rated as 2++, directly applicable to the target population, and demonstrating overall consistencyof results; or extrapolated evidence fromstudies rated as 1++or 1+;C5 a bodyof evidence including studies rated as 2+, directly
applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++; D5 evidence level 3 or 4; or extrapolated evidence from studies rated as 2+.
†Definitions for Levels of Evidence (see Appendix A, Table 1): 1++ High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias; 1+ well-conducted
meta analyses, systematic reviews of RCTs, or RCTs with a low risk of bias; 12Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2++ high-quality systematic reviews of case-control or cohort
studies; or high quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+Well conducted case-control or cohort studies with a low
risk of confounding, bias, or chance, and a moderate probability that the relationship is causal; 22Case-control or cohort studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship
is not causal; 3 Nonanalytic studies (eg, case reports, case series); 4 Expert opinion.
‡The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence described in each section of the review.
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Table 2. Transplantation vs. Chemotherapy for Adult Acute Lymphoblastic Leukemia in First Complete Remission
Reference and Patient
Populations
Quality/
Strength of
Evidence*
Treatment
Regimen
Sample
Size
Age, Yeas
Median (range)
%
WBC
>100,000
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS
/LFS
†
% OS (95%CI)
Signif.
OS
†
Update data published since January 2005
[2] Ram 2010 1++ Total 1863 NR (7-60) NR NR NR Overall Mean NR NR NR Reduced ACM P 5 .009
1986-2006 accrual dates Allo SCT 62 (30-110) for Allo SCT
Meta-analysis Other (auto or chemo) RR, .89
Aggregate data from (7 ITT trials) (0.82-0.97)
11 studies (9 ITT)
Total 903 No difference P 5 .76
Auto SCT in ACM
Chemotherapy RR, 1.02
(5 randomized trials) (0.88-1.19)
[3] Orsi 2007 1++ Total 772 NR NR NR NR NR NR 5-year EFS P 5 .011 NR NR
2000-2007 accrual dates Donor 293 44.2% ± 2.9% Donor vs.
Meta-analysis No Donor 479 36.7% ± 2.2% No Donor
Individual data from
4 pre-2005 studies
[5] Dhedin 2006 1++ Total 349 $30,000 5% 120 (NR) ITT 10-yr DFS P 5 .12 10-year OS P 5 .48
1985-2001 accrual dates Autologous SCT 175 28 (15-50) 43% 42% 6% 28% (21-35%) 30% (23-38%)
Meta-analysis Chemotherapy 174 33 (15-50) 36% 43% 2% 19% (13-26%) 22% (16-30%)
Individual data from
3 randomized trials:
LALA-85, -87, -94
[4] Yanada 2006 1+ Total 1274 NR NR NR NR NR NR NR NR Summary HR P 5 .037
1986-2002 accrual dates Donor 503 for OS was Donor vs.
Meta-analysis No Donor 771 1.29 No Donor
Aggregate data from (1.02-1.63)
7 studies favoring Donor
vs. No Donor
[6] Goldstone 2008 1+ Total 456 NR (15-64) NR 4% NR 59 (1-167) NR 5-yr EFS P 5 .02 5-year OS P 5 .03
1993-2006 Autologous SCT 229 32% Chemo vs. 37% (31-44%) Chemo vs.
Prospective, Multicenter Chemotherapy 227 41% Auto SCT 46% (39-53%) Auto SCT
MRC UKALL XII & (Randomized)
ECOG E2993 (includes 16 Ph+ pts.)
(Included in Ram, 2010
meta-analysis) 2++ Total 1031 NR (15-64) NR 0% NR 59 (1-167) NR NR NR 5-year OS
Donor (MSD Allo) 443 SR P 5 .02
No Donor (chemo or auto) 588 62% Donor vs.
(Ph- patients only) 52% No Donor
HR
‡
41% P 5 .20
35%
[7] Marks 2009 1+ Total 99 29 (15-59) 27% NR 100% 84 (3-192) NR NR 5-year OS P 5 .90
1993-2006 Autologous SCT 54 NR 51% (37-64%)
Prospective, Multicenter Chemotherapy 45 NR 51% (36-65%)
MRC UKALL XII & (Randomized)
ECOG E2993
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Table 2. (Continued )
Reference and Patient
Populations
Quality/
Strength of
Evidence*
Treatment
Regimen
Sample
Size
Age, Yeas
Median (range)
%
WBC
>100,000
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS
/LFS
†
% OS (95%CI)
Signif.
OS
†
T-lineage ALL only 2+ Total 249
Donor (MSD Allo) 110 22% NR NR 61% (51-70%) P 5 .02
No Donor (chemo
or auto)
139 12% 46% (38-55%)
[8] Ribera 2005 1+ Total 98 NR 14% 70 (27-113) ITT 5-year DFS P 5.19 5-year OS P 5 .17
1993-2002 Autologous SCT 50 25 (25-50) 34% 2% 35% ± 12% 37% ± 12%
Prospective, Multicenter Chemotherapy 48 27 (15-50) 25% 2% 44% ± 12% 50% ± 12%
Spanish PETHEMA (Randomized)
ALL-93
HR
§
ALL in CR1 2+ Total 222 27 (15-50) NR 23% 30% 70 (27-113) ITT 5-year DFS P not signif 5-year OS P not signif
(Included in Ram, 2010 Donor (MRD Allo) 84 10% 39% (30-48%) 44% (35-52%)
and Yanada, 2006
meta-analyses)
No Donor (chemo
or auto)
98 2% 33% (23-41%) 35% (25-44%)
[9] Hunault 2007 1+ Total 27 NR 100% 85.2 (NR) NR ITT 7-year RFS P not signif 7-year OS P not signif
1994-1998 Autologous SCT 10 21 (15-59) 0% 60% ± 15% 70% ± 14%
Prospective, Multicenter Maintenance Chemo 17 NR 0% 65% ± 12% 65% ± 12%
GOELAMS T-LBL/ALL (Randomized)
GOELAL02
T-lineage ALL only
[11] Fielding 2009 2++ Total 158 40 (15-60) NR 100% < 1% 98 (38-171) ITT 5-year OS P 5 .20
1993-2004 Donor (MSD Allo) 81 NR 34% (24-45%)
Prospective, Multicenter No Donor 77 NR 25% (15-34%)
MRC UKALL XII and (ITT)
ECOG E2993 5-year EFS P <.001 5-year OS P 5 .001
Ph+ ALL in CR1 2++ MSD Allo SCT 45 27% 41% (27-56) Any Allo 44% (29-59%) Any Allo
MUD Allo SCT 31 39% 36% (19-52) vs. Chemo 36% (19-52%) vs. Chemo
Chemotherapy 82 NR 9% (3-15%) 19% (10-28%)
(By actual treatment)
[12] Li 2010 2++ Total 110 >30,000 NR 2-year DFS P 5 .003 2-year OS P < .001
1996-2007 Allo SCT 22 32 (16-51) 40.9% 54.5% 18 (7-14) 5% 48.2% ± 13.9% Allo SCT 53.1% ± 12.7% Allo SCT
Retrospective, Single Ctr Chemo + Imatinib (ICT) 41 36 (15-59) 53.7% 58.5% 12.5 (2-46) 2% 22.1% ± 8.8% vs. CT 41.6% ± 10% vs. CT
Ph+ or BCR-ABL+ ALL Chemotherapy (CT) (pre- 47 33 (15-56) 63.8% 51.1% 11 (2-32) 2% 0% P 5 .016 23.2% ± 6.9% P 5 .009
87.3% in CR1 imatinib era pts) ICT vs. CT ICT vs. CT
[13] Yanada 2006 2+ Total 102 48 (15-63) NR NR NR 13.1 (2-35) NR NR 1-year OS P 5 .94
2002-2005 MSD, MRD, MUD Allo,
Prospective, Multicenter or UCBT 49 27% 73.3% ± 6.9%
JALSG ALL-202 No Allo SCT 53 NR 84.8% ± 7.1%
(Chemo + Imatinib) (Chemo+imatinib or
vs. JALSG ALL-93 chemo alone)
(Chemo only)
Ad hoc, 49 Allo SCT
BCR-ABL+ ALL
(Continued )
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Table 2. (Continued )
Reference and Patient
Populations
Quality/
Strength of
Evidence*
Treatment
Regimen
Sample
Size
Age, Yeas
Median (range)
%
WBC
>100,000
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS
/LFS
†
% OS (95%CI)
Signif.
OS
†
Original Adult ALL EBR data
[14] Fiere 1993 1+ Total 191 > 30,000 38 (NR) ITT 3-year DFS P 5 .80 3-year OS P 5.90
1986-1991 Autologous BMT 95 25 (15-50) 37% 7% 40% 4% 39% ± 5% 49% ± 5%
Prospective, Multicenter Chemotherapy 96 28 (15-48) 33% 21 30% 3% 32% ± 5% 42% ± 6%
LALA-87 (Randomized)
[18] Thomas 2004 1+ Total
¶
129 33 (15-55) NR 23% 26% 62 (NR) 3-year DFS P not signif 3-year OS P not signif
1994-2002 Autologous SCT 70 7% 39% 44%
Prospective, Multicenter Chemotherapy 59 0% 24% 35%
LALA-94 (Randomized)
2+ Total 259 3-year DFS P 5 .007 NR NR
Related donor Allo 100 18% 47% Donor vs.
No donor (chemo
or auto)
159 7% 34% No Donor
[17] Sebban 1994 2++ Total 257 > 30,000 62 (10-90) ITT 5-year DFS P 5 .10 5-year OS P 5.08
1986-1991 Related donor Allo 116 26 (15-40) 42% 6% 33% 16% 45% ± 5 48% ± 5
Prospective, Multicenter No donor (chemo
or auto)
141 24 (15-40) 40% 13% 38% 3% 31% ± 4 35% ± 5
LALA-87
ALL in CR1 or CR2
[19] Zhang 1995 2++ Total 718 NR (15-45) NR NR NR 9-year LFS P >.20 NR NR
1980-1987 MSD Allo BMT 234 100 (28-162) 53% 34% (28-40%)
Retrospective, Multictr Chemotherapy 484 89 (12-156) 5% 32% (27-37%)
IBMTR & two trials
[16] Oh 1998 2++ Total 290 5-year LFS NR NR
1988-1990 # 30 y # 30 y P 5.02
Retrospective, Multictr MSD Allo BMT 214 26 (15-51) 19% 13% 29% 48 (7-81) 32% 53% (44-63%) Allo vs.
IBMTR and Chemotherapy 76 29 (15-55) 16% 8% 21% 54 (2-80) 3% 30% (15-48%) Chemo
JALSG All-87 > 30 years > 30 years P 5 .70
57% 30% (20-41%)
13% 26% (13-41%)
[15] Messerer 1991 2++ Total 76 NR (15-44) NR NR NR NR NR 3-year DFS P not signif NR NR
Prospective MSD Allo BMT 38 34% (16-52%)
German ALL/AUL Chemotherapy 38 34% (16-52%)
ACM indicates all-cause mortality; ALL, acute lymphoblastic leukemia; Allo, allogeneic; Auto, autologous; BFM, Berlin-Frankfurt-M€unster; BMT, bone marrow transplantation; Chemo, chemotherapy; CI, confidence
interval; CR, complete remission; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; EFS, event-free survival; GOELAMS, Groupe Ouest Est d’Etude des Leucemies et Autres Maladies du Sang;
HR, high risk; IBMTR, International Bone Marrow Transplant Registry; ITT, intention-to-treat analysis; JALSG, Japan Adult Leukemia Study Group; LALA, Leucemie Aigu€es Lymphoblastique de l’Adulte; LFS, leukemia-
free survival; MMRD, mismatched related donor; MRC, Medical Research Council; MRD, matched related donor; MSD, matched sibling donor; MUD, matched unrelated donor; NR, not reported; Ph+, Philadelphia
chromosome-positive; OS, overall survival; PETHEMA, Programa para el Tratamiento de Hemopatıas Malignas; SCT, stem cell transplantation; SR, standard risk; TRM, treatment-related mortality; UCBT, unrelated
cord blood transplant; WBC, white blood cell.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
‡HR 5 age >35, WBC $100  109/L; SR 5 all others.
§HR 5 at least one of the following: age 30-50, WBC $25  109/L, Ph+, t(4;11) or other 11q23 rearrangement, t(1;19).
¶Patient characteristic and median follow-up data based on 922 total patients in study.
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Table 3. Transplantation vs. Chemotherapy for Refractory or Relapsed Adult Acute Lymphoblastic Leukemia
Reference and Patient
Populations
Quality/
Strength of
Evidence*
Treatment
Regimen
Sample
Size
Age, Years
Median
(range)
% WBC
>100,000 % Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
% EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS/
LFS
†
% OS (95%CI)
Signif.
OS
†
Update data published since January 2005
[20] Fielding 2007 2++ Total 302 NR (15-60) NR 33% NR 54 (1-131) NR NR NR 5-year OS P <.001
Prospective, Multicenter MSD Allo SCT 42 23% (10%-36%) Any SCT
Subset analysis of MUD Allo SCT 65 16% (7%-26%) vs. Chemo
MRC UKALL XII & Autologous SCT 13 15% (0%-35%)
ECOG 2993 Chemotherapy 182 4% (1%-7%)
ALL in 1st relapse (By actual treatment)
(Duration of CR1 NR)
[21] Cornillon 2005 2+ Total 46 20 (4-50) NR 53% NR 54 (20-118) NR NR NR 4-year OS P <.007
1993-2000 Donor (MSD Allo) 21 Data not Donor vs.
Retrospect., Single Ctr No Donor (chemo or auto) 25 provided No Donor
Refractory ALL (63%) (By actual treatment)
Total (ALL & AML) n 5 97 4-year OS for
ALL only n 5 46 ALL overall
(Duration of CR1 NR) 12%
ALL indicates acute lymphoblastic leukemia; Allo, allogeneic; AML, acute myeloid leukemia; Auto, autologous SCT; Chemo, chemotherapy; CI, confidence interval; CR, complete remission; DFS, disease-free survival;
ECOG, Eastern Cooperative Oncology Group; EFS, event-free survival; LFS, leukemia-free survival; MRC, Medical Research Council; MSD, matched related donor; MUD, matched unrelated donor; NR, not reported;
OS, overall survival; TRM, treatment-related mortality; SCT, stem cell transplantation; WBC, white blood cell.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
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Biol Blood Marrow Transplant 18:18-36, 2012 25The Role of Cytotoxic Therapy with Hematopoietic SCT
in the Treatment of ALLsurvival or OS among adult patients with T-lineage
ALL in CR1 randomized to autologous SCT versus
chemotherapy alone.
Donor versus No Donor
Goldstone et al. [6] also compared Philadelphia
chromosome-negative (Ph-negative) patients in a do-
nor versus no-donor analysis and reported a significant
difference in 5-year OS in favor of standard risk
Ph-negative patients with a donor versus no donor,
but no difference in OS for high-risk Ph-negative pa-
tients. An unplanned subset analysis [10] reported
the benefit of having a donor was greater in high-risk
younger (\35 years) versus older patients; however,
the difference was not significant.
Marks et al. [7] reported a significant benefit in
5-year OS for T-lineage ALL patients receiving sib-
ling donor SCT versus no donor therapy (autologous
SCT or chemotherapy); a difference that was main-
tained at 10 years.
Ribera et al. [8] reported no significant difference in
5-yearDFS orOS between high risk patients with ALL
in CR1 who had a donor versus those with no donor.
Fielding et al. [11] found no significant difference in
5-year OS between Ph1 ALL patients in an
intention-to-treat donor versus no-donor analysis;
however, a significant difference in 5-year EFS and
OS was reported in favor of Ph1 ALL patients whose
actual treatment was an HLA-matched related or
HLA-matched unrelated allogeneic SCT versus those
who received chemotherapy alone.Allogeneic SCT versus Chemotherapy ± Imatinib
in Ph1/BCR-ABL1 ALL
In a retrospective study by Li et al. [12], Ph1 or
BCR-ABL1 ALL patients who received chemother-
apy combined with imatinib or underwent an HLA-
matched related donor or HLA-compatible donor
unrelated allogeneic SCT had significantly better
2-year DFS and 2-year OS compared with patients
(preimatinib era) who received chemotherapy alone.
Patients who underwent allogeneic SCT also had
better survival outcomes than those in the chemother-
apy1 imatinib group, although there was no statistical
significance.
In a prospective, multicenter study, Yanada et al.
[13] reported no significant difference in 1-year OS
between adult patients with BCR-ABL1 ALL who
underwent an HLA-matched related or unrelated allo-
geneic SCT versus those who did not undergo trans-
plantation, but received chemotherapy 1 imatinib or
chemotherapy alone.
Original ALL EBR Studies
The six high-quality studies [14-19] from the
original adult ALL EBR provided seven analyses,including two randomized autologous SCT versus
chemotherapy, two donor versus no donor, and three
allogeneic bone marrow transplantation (BMT) versus
chemotherapy for the treatment of adult ALL in CR1.
The quality ratings of these studies ranged from 11
to 21. The majority of these studies reported no
significant outcome differences; however, one study
reported a donor versus no donor (autologous SCT or
chemotherapy) advantage in 3-year DFS [18]. Another
study reported a significantly better 5-year leukemia-
free survival (LFS) in favor of an HLA-matched sibling
allogeneic SCT versus chemotherapy alone, but only
for patients#30 years of age [16].
Transplantation versus Chemotherapy for
Refractory or Relapsed Adult ALL
Table 3 presents two studies published since the
original ALL EBR, which compared transplantation
versus chemotherapy as treatment for relapsed or re-
fractory adult ALL.
Fielding et al. [20] reported a significantly better
5-year OS for adult patients with ALL in first relapse
whose actual treatment was any type of SCT (HLA-
matched sibling or HLA-matched unrelated allogeneic
SCT or autologous SCT) versus those who received
chemotherapy alone.
Cornillon et al. [21] reported a significant im-
proved in 4-year OS for adult patients with refractory
ALL who actually received an HLA-matched sibling
allogeneic SCT versus chemotherapy or autologous
SCT (based on donor availability).
There were no studies in the original adult ALL
EBR that compared transplantation versus chemother-
apy for refractory or relapsed ALL, or for ALL inCR2.AUTOLOGOUS VERSUS ALLOGENEIC SCT
FOR ADULTALL
There were two studies published since the origi-
nal ALL EBR, and briefly summarized below, which
compared the outcomes of autologous versus myeloa-
blative allogeneic SCT as treatment for adult ALL.
The quality of these studies were 211 and 21.
Table 4 summarizes the study designs, patient popula-
tions, and outcomes from this new evidence.
A donor (allogeneic SCT) versus no-donor (autol-
ogous SCT) analysis by Cornelisson et al. [22] re-
ported a significantly better 5-year DFS for adult
standard risk ALL patients with an HLA-matched re-
lated donor who underwent allogeneic SCT versus
those without a donor who underwent autologous
SCT.
Bishop et al. [23] found equivalent outcomes in
5-year LFS or OS for high-risk adult ALL patients
in CR1 or CR2 who underwent an unrelated donor
allogeneic SCT versus an autologous SCT.
Table 4. Allogeneic SCT vs. Autologous SCT for Adult ALL
Reference and Patient
Populations
Quality/
Strength
of Evidence*
Treatment
Regimen
Sample
Size
Age, Years
Median (range)
%
WBC
>100,000
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS/
LFS
†
% OS (95%CI)
Signif.
OS
†
Update data published since January 2005
[22] Cornelissen 2009 2++ Total 257 NR 5-year DFS P 5 .01 5-year OS P 5.08
1992-2005 Donor (Allo SCT) 96 31 (16-55) 15% 22% 29% 16% 60% ± 5% Donor vs. 61% ± 5%
Prospective, Multicenter No Donor (Auto SCT) 161 26 (15-54) 11% 16% 24% 3% 42% ± 4% No Donor 47% ± 5%
HOVON-18 and -37
SR ALL in CR1
[23] Bishop 2008 2+ Total 260 >50,000 NR 2-year 5-year LFS P 5 .50 5-year OS P 5.46
1989-1998 URD Allo SCT 159 27 (18-51) 52% 16% 84 (36-170) 45% 33% 34%
Retrospective, Registry Autologous SCT 101 28 (18-51) 68% 21% 74 (12-141) 9% 29% 29%
NMDP & CIBMTR
HR
‡
ALL in CR1 or
CR2 (46% in CR2)
Original adult ALL EBR data
[24] Ringden 2000 2++ Total ALL only 1785 Overall NR NR Overall 32 (NR) 2-year 5-year LFS P < .0001 NR NR
1987-1999 MSD Allo SCT 346 27 (1-66) 5% 9% 61% ± 3% Any Allo
Retrospective, Multictr Twin Allo SCT 23 30 (1-70) 3% 17% 54% ± 11% vs. Auto
EBMTR Autologous SCT 1416 34 (1-77) 4% 9% 44% ± 1% (ALL)
ALL in CR1 (39%) (ALL) (ALL)
[27] Hunault 2004 2+ Total 156 14% 61 (NR) 6 month 6-year DFS P 5 .0004 6-year OS P 5 .0027
1994-1998 Donor (MSD Allo) 41 34 (15-52) 24% 7% 15% 72% ± 7% Donor vs. 75% ± 7% Donor vs.
Prospective, Multicenter No Donor (Auto SCT) 115 27 (15-59) 13% 6% 3% 33% ± 6% No Donor 39% ± 7% No Donor
GOELAMS GOELAL02
ALL (86% in CR1)
[18] Thomas 2004 2+ Total 140 33 (15-55) NR 100% 0% 62 (NR) NR 3-year DFS P 5 .001 3-year OS P 5 .009
1994-2002 MRD or MUD Allo SCT 75 34% Allo vs. Auto 36% Allo vs.
Prospective, Multictr Autologous SCT 65 15% 17% Auto
LALA-94
Ph+/BCR-ABL+ only
ALL in CR1
[25] Attal 1995 2+ Total 120 31 (15-55) NR 3-year DFS P < .001 NR NR
1990-1992 Donor (MSD Allo) 42 12% 37% 30.3 (NR) 12% 68% (51%-80%) Donor vs.
Prospective, Multicenter No Donor (Auto SCT) 77 18% 24% 29.1 (NR) 2% 26% (16%-37%) No Donor
ALL in CR1
[26] Dombret 2002 2+ Total 103 42 (17-56) NR 100% 0% 54 (NR) NR NR NR ITT 3-year OS P 5 .02
1994-2000 Donor (MRD or MUD) 60 37% (24%-49%)
Prospective, Multicenter No Donor (Auto SCT) 43 12% (4%-24%)
LALA-94
Ph+/BCR-ABL+ only
ALL in CR1
ALL indicates acute lymphoblastic leukemia; Allo, allogeneic; Auto, autologous; CI, confidence interval; CIBMTR, Center for International Blood and Marrow Transplant Research; CR, complete remission; EBMTR, European
Group for Blood and Marrow Transplantation; EFS, event-free survival; GOELAMS, Groupe Ouest Est d’Etude des Leucemies et Autres Maladies du Sang; HOVON, Dutch-Belgian Cooperative Trial Group for Hematology
Oncology; ITT, intention-to-treat; LALA, Leucemie Aigu€es Lymphoblastique de l’Adulte; MRD, matched related donor; MSD, matched sibling data; MUD, matched unrelated donor; NMDP, National Marrow Donor Program;
NR, not reported; OS, overall survival; Ph+, Philadelphia chromosome-positive; SCT, stem cell transplantation; SR, standard risk; TRM, treatment-related mortality; URD, unrelated donor; WBC, white blood cell.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
‡HR 5 t(4;11), 11q23, Ph+, t(8;14), t(1;19), or hypodiploidy.
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Table 5. Related vs. Unrelated Allogeneic SCT for Adult ALL
Reference and Patient
Populations
Quality/
Strength of
Evidence*
Treatment
Regimen
Sample
Size
Age, Years
Median
(range)
Median
Duration
CR1 (Months)
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS /
LFS
†
% OS (95%CI)
Signif.
OS
†
Update data published since January 2005
[28] Ringden 2009 2++ Total (ALL only) 672 Overall > 12 months NR NR Overall NR 5-year LFS P 5 .67 NR NR
1995-2004 MSD Allo SCT 483 38 (18-60) 29% 60.3 (1-137) for RR, 1.05
Retrospective, Registry MUD Allo SCT 189 39 (18-60) 35% 72.2 (10-135) ALL (0.84-1.32)
CIBMTR (Overall) only No difference
Total n 5 4099 between MSD
ALL 16% (stratified) and MUD for
(Others—AML, CML) ALL patients
[29] Lee 2007 2++ Total 201 NR 63 (25-139+) NRM 5-year DFS P 5 .086 5-year OS P 5 .067
1995-2004 MSD Allo SCT 152 31 (15-52) 34.2% 14.4% 21.4% 49.5% ± 4.1% 52.4% ± 4.1%
Retrospective, Single Ctr MUD/MMUDAllo SCT 49 22 (15-48) 30.6% 12.2% 29.3% 42.9% ± 7.1% 42.1% ± 7.2%
ALL (75% in CR1)
88.6% HR
[30] Dahlke 2006 2+ Total 84 23 (1-60) NR 31% 17% 18 (1-133) 27% 3-year DFS P 5 .86 3-year OS P 5 .71
1990-2001 MRD/MMRD Allo SCT 46 (Mean) 46% 44%
Retrospective, Single Ctr MUD/MMUDAllo SCT 38 44% 42%
HR ALL (51% in CR1)
58% $ 18 years
[31] Chim 2007 22 Total 108 33 (15-56) NR 35.2% NR 20.5 (1-195) 15-year DFS P 5 .03 15-year OS P 5 .10
1990-NR MSD Allo BMT 87 17.3% 28.2% 31.6%
Retrospective, Single Ctr MUD Allo BMT 21 14.9% 63.2% 67.8%
ALL (67% in CR1)
[32] Cho 2009 22 Total 37 45 (15-63) NR 43.2% 10.8% 36 (12-96+) 17.7% 3-year DFS P 5 .72 3-year OS P 5 .58
2000-2007 MSD Allo SCT 27 65% ± 9.6% 67.8% ± 9.7%
Prospective, Single Ctr MUD/MMUDAllo SCT 10 56% ± 17.1% 52.5% ± 18.6%
HR ALL (81% in CR1)
RIC
ALL indicates acute lymphoblastic leukemia; Allo, allogeneic; AML, acutemyeloid leukemia; BMT, bonemarrow transplantation; CI, confidence interval; CIBMTR, Center for International Blood andMarrow Transplant
Research; CML, chronic myeloid leukemia; CR, complete remission; DFS, disease-free survival; EFS, event-free survival; HR, high risk; LFS, leukemia-free survival; MMRD, mismatched related donor; MMUD, mis-
matched unrelated donor; MRD, matched related donor; MSD, matched sibling donor; MUD, matched unrelated donor; NR, not reported; Ph+, Philadelphia chromosome-positive; OS, overall survival; RIC,
reduced-intensity conditioning; SCT, stem cell transplantation; TRM, treatment-related mortality.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
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28 Biol Blood Marrow Transplant 18:18-36, 2012D. M. Oliansky et al.The details of one high-quality registry study (211)
[24] and four multicenter studies (rated 21) [18,25-27],
which were used to make a treatment recommendation
in the original adult ALL EBR regarding the use of
autologous SCT versus allogeneic SCT, are presented
in Table 4. All five studies found a significant improve-
ment inDFS or LFS, and/orOS for patients who under-
went an HLA-matched related or HLA-matched
unrelated donor allogeneic SCTversus autologousSCT.RELATED VERSUS UNRELATED ALLOGENIC
SCT FOR ADULTALL
There were five studies published since the origi-
nal ALL EBR, and summarized briefly below, which
compared related versus unrelated donor allogeneic
SCT as treatment for adult patients with ALL. Table
5 presents a detailed summary of the study designs, pa-
tient populations, and outcomes from this new evi-
dence, ranging in quality from 211 to 22. Recent
and continuing improvements in unrelated donor
HLA typing and selection impacting overall outcomes
are not reflected in the earlier reports.
In a retrospective analysis of the Center for Inter-
national Blood andMarrow Transplant Research data,
Ringden et al. [28] reported no difference in 5-year
LFS between adult ALL patients who underwent an
HLA-matched sibling allogeneic SCT versus an
HLA-matched unrelated donor allogeneic SCT.
In a retrospective analysis of single center data,
Lee et al. [29] reported comparable 5-year DFS and
5-year OS in adult ALL patients who underwent an
HLA-matched sibling donor allogeneic SCT versus
an HLA-matched or mismatched unrelated donor
allogeneic SCT.
Dahlke et al. [30] reported comparable 3-year DFS
and 3-year OS in older adult patients (58%$58 years)
who underwent an HLA-matched or mismatched
related allogeneic SCT versus an HLA-matched or
mismatched unrelated donor allogeneic SCT.
In a long-term retrospective analysis of single cen-
ter data, Chim et al. [31] reported significantly better
15-year DFS, but no difference in 15-year OS, in adult
ALL patients who underwent an HLA-matched unre-
lated donor allogeneic BMT versus an HLA-matched
sibling allogeneic BMT.
Cho et al. [32] reported no significant difference in
3-yearDFS or 3-yearOS in a prospective, single center
study of adult patients with ALL (majority in CR1)
who underwent an HLA-matched sibling allogeneic
SCT versus an HLA-matched or unmatched unrelated
donor allogeneic SCT following a reduced-intensity
conditioning (RIC) regimen.
In the original adult ALL EBR there was one mul-
ticenter study that compared related versus unrelated
allogeneic SCT.Kiehl et al. [33] reported no significantdifference in 5-year DFS in 221 patients with ALL in
CR1 who underwent an HLA-matched related versus
an HLA-matched unrelated allogeneic SCT (21 rat-
ing; not presented in Table 5).OTHER COMPARATIVE STUDIES OF ADULT
ALL
There were 12 comparative studies published since
the original ALL EBR, and summarized briefly below,
which investigated the impact of transplantation-
related factors, such as hematopoietic cell source (unre-
lated bone marrow versus cord blood, n 5 2 studies),
pre- and/or post-SCT imatinib therapy (n 5 4 studies),
induction therapy regimen (n 5 2 studies), induction
versus no reinduction therapy (n5 1 study), and condi-
tioning regimen (n5 3 studies) on survival outcomes in
adult patientswithALL.Table 6presents a detailed sum-
mary of the study designs, patient populations, and out-
comes from this new evidence. The quality ratings of
these 12 studies ranged from 111 to 21. There were
no comparable studies in the original adult ALL EBR.
Unrelated Donor Bone Marrow (BM) versus
Cord Blood SCT
Ferra et al. [34] reported no significant difference
in 5-year DFS or 5-year OS between adult high risk
ALL patients who underwent an unrelated donor
BMT versus a cord blood transplantation. Similarly,
Atsuta et al. [35] reported no significant difference in
2-year LFS or 2-year OS between adult ALL patients
who underwent an unrelated donor BMT versus a cord
blood transplantation.
Imatinib versus No Imatinib Therapy
In a retrospective, registry analysis, Mizuta et al.
[36] reported significantly improved 3-year DFS and
3-year OS in adult Ph1 ALL patients who received
imatinib therapy pre- and/or post-allogeneic SCT ver-
sus those in a preimatinib era historical control who
did not. In a prospective, multicenter study, Bassan
et al. [37] also reported significant improvement in
5-year DFS and 5-year OS in adult Ph1 ALL patients
who received imatinib therapy pre- and/or post-SCT
(autologous or allogeneic) versus those who did not
receive imatinib. In addition, Lee et al. [38] reported
significantly improved 3-year DFS and 3-year OS in
adult Ph1 ALL patients who received imatinib ther-
apy pre- and/or post-allogeneic SCT versus those in
a preimatinib era historical control who did not. In
a retrospective, single center study, Burke et al. [39]
reported no significant difference in 2-year LFS or
2-year OS between adult Ph1 ALL patients who
received imatinib therapy pre- and/or postallogeneic
SCT versus those who did not receive imatinib or
who received it only after relapse.
Table 6. Other Comparative Studies of Adult ALL
Reference and Patient
Populations
Quality/
Strength of
Evidence* Treatment Regimen Sample Size
Age, Years
Median
(Range)
Median
Duration
CR1 (Months)
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS
/LFS
†
% OS (95%CI)
Signif.
OS
†
Update data published since January 2005
UNRELATED DONOR BMT VS. UNRELATED CORD BLOOD TRANSPLANT
[34] Ferra 2010 2++ Total 149 29 (15-59) NR 5-year DFS P 5 NS 5-year OS P 5 NS
2000-2007 URD Allo SCT 87 59% 16% 20 (.3-96) 48% 21% (11-31%) 22 (11%-33%)
Retrospective, Multictr single UCBT 62 63% 23% 23 (2.7-101) 31% 22% (8-36%) 33 (18%-48%)
HR ALL (54% in CR1)
[35] Atsuta 2009 2+ Total (ALL only) 336 NR NR NR 2-year 2-year LFS P 5 .06 2-year OS P 5 .40
2000-2005 URD Allo BMT 222 32 (16-59) 23% 25% 51% 57%
Retrospective, Registry single UCBT 114 34 (16-58) 38% 24% 45% 49%
JCBBN & JMDP
Total n 5 820 (inc. AML)
ALL 41% (stratified)
57% ALL in CR1
IMATINIB VS. NO IMATINIB THERAPY PRE- AND/OR POST-SCT IN PH+ ALL
[36] Mizuta 2010 2++ Total 173 NA 100% NR 3-year DFS P 5 .039 3-year OS P 5 .015
2002-2005 Imatinib Pre Allo 51 38 (15-64) 31.2 (12-55) 58% (42-71%) 65% (49%-78%)
Retrospective, Registry No Imatinib (pre-imatinib 122 38 (15-57) 82.8 (12-137) 37% (29-46%) 44% (35%-52%)
JALSG ALL 202, historical control)
JSHCT, and JMDP
Ph+ ALL in CR1
[37] Bassan 2010 2++ Total 94 NA 100% NR 60 (7-110) 5-year DFS P 5.044 5-year OS P 5 .009
2000-NR Imatinab Pre/Post SCT 59 45 (20-66) 18% 39% (26-52%) 38% (19-57%)
Prospective, Multicenter No Imatinib Pre/Post SCT 35 50 (20-66) 13% 25% (8-37%) 23% (8-34%)
NILG 09/00 trial
Ph+ ALL (87% in CR1) (SCT 5Allo or Auto)
[38] Lee 2005 2+ Total 62 NA 100% NR NRM 3-year DFS P < .001 3-year OS P < .001
2000-2003 Imatinib Pre Allo 29 36 (18-55) 25 (12-45+) 18.7% 78.1% ± 11.6% 78.1% ± 11.6%
1996-2000 Historical 5-year DFS 5-year OS
Prospective, Single Ctr No Imatinib (pre-imatinib 33 35 (15-48) 51 (40-72+) 27% 38.7% ± 8.8% 38.7% ± 8.8%
Ph + ALL (86% in CR) historical control)
[39] Burke 2009 2+ Total 32 Mean NR NR 11 (1-58) 2-year RFS P 5 .12 2-year OS P 5 .19
1999-2006 Imatinab Pre/Post Allo SCT 15 18 (1-42) 87% 20% 67% 61%
Retrospective, Single Ctr No Imatinab Pre/Post SCT 17 29 (3-55) 100% 29% 35% 41%
Ph+ ALL (63% in CR1) (or only after relapse)
COMPARISON OF INDUCTION THERAPIES
[40] Labar 2010 1++ Total 325 CR rate 79.2 (6-140) 6-year EFS P 5 .82 6-year OS P 5 .45
1995-2003 Dexamethasone 163 32 (15-68) 80.4% 18% 31% 18.3% 25.9% ± 3.6% 30.6%
Prospective, Multicenter Prednisolone 162 34 (15-72) 76.5% 17% 25% 10.5% 28.7% ± 3.5% 35.2%
EORTC ALL-4 (Randomized)
Untreated ALL (prior to allo, auto, or chemo)
(Continued )
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Table 6. (Continued )
Reference and Patient
Populations
Quality/
Strength of
Evidence* Treatment Regimen Sample Size
Age, Years
Median
(Range)
Median
Duration
CR1 (Months)
%
Ph+
% T
Lineage
Follow-Up
(in Months)
Med (Range)
%
TRM
%
EFS/DFS/LFS
(95% CI)
Signif.
EFS/DFS
/LFS
†
% OS (95%CI)
Signif.
OS
†
[41] Wassmann 2006 2+ Total 92 CR rate 100% NR NR NR NR 2-year OS P 5 .97
2001-2004 Alternating Chemo + Imatinib 47 46 (21-65) 78% 36.2% ± 7%
Prospective, Multicenter Concurrent Chemo + Imatinib 45 41 (19-63) 56% 43% ± 9%
Ph+ ALL (77% in CR1) (prior to allo or auto SCT)
COMPARISON OF REINDUCTION VS. NO REINDUCTION THERAPY PRE-ALLO SCT ± DLI FOR REFRACTORY/RELAPSED ALL
[42] Terwey 2008 2+ Total 60 NR NR NR 5-year OS P5 .039
1995-2006 No Reinduction (31% DLI) 19 34 (18-49) 37% 10% 68 (28-109) 26% 47%
Retrospective analysis Reinduction (40% DLI) 41 26 (17-54) 17% 29% 25.8 (17-141) 34% 18%
Single Center (prior to allo SCT)
Refract/Relapsed ALL
COMPARISON OF CONDITIONING REGIMENS
[43] Marks 2010 2++ Total 1521 >12 mo 0% 3-year 3-year DFS P 5 .12 3-year OS P 5 .39
1995-2006 Myeloablative 1428 28 (16-62) 54% 21% 54 (3-166) 33% 41% (38%-44%) 43% (40-46%)
Retrospective, Registry RIC 93 45 (17-66) 61% 20% 38 (3-93) 32% 32% (22%-43%) 38% (28-49%)
CIBMTR (MSD or URD Allo SCT)
Ph-negative ALL
(53% in CR1)
[44] Kojima 2005 2+ Total (ALL only) 35 (Overall) NA NR NR (Overall) (ALL) NR NR 2-year OS (ALL) P 5 NR
1998-2002 Myeloablative 27 52 (50-59) 31.6 (10-64) 41% 33% (16%-51%)
Retrospective, Multictr RIC 8 57 (50-59) 20.3 (10-38) 25% 50 (15%-85%)
Total 207 (prior to allo SCT)
ALL n 5 35 (stratified)
(AML, CML, MDS)
[45] Deconinck 2005 2+ Total 35 NA 4-year EFS P 5 .02 4-year OS P 5 .009
1986-1992 Standard Ind. & Cond. 18 20 (17-40) 11% 33% 121 (114-157) 11% 66% ± 11% 71% ± 12%
Retrospective, Multictr Intensive Ind. and Cond. 15 29 (19-46) 27% 20% 47 (39-51) 40% 35% ± 11% 36% ± 13%
LALPOF (standard) (actually rec’d allo SCT)
GOLEAL1 (intensive)
ALL in CR1
ALL indicates acute lymphoblastic leukemia; Allo, allogeneic; AML, acute myeloid leukemia; Auto, autologous; CI, confidence interval; CIBMTR, Center for International Blood and Marrow Transplant Research; CML,
chronic myeloid leukemia; Cond., conditioning; CR, complete remission; DFS, disease-free survival; DLI, donor lymphocytic infusions; EFS, event-free survival; EORTC, European Organization for Research and
Treatment of Cancer; GOLEAL, Groupe Ouest Est des Leucemies Aigu€es Lymphoblastiques; HR, high risk; Ind., induction; JALSG, Japan Adult Leukemia Study Group; JCBBN, Japan Cord Blood Bank Network;
JMDP, Japan Marrow Donor Program; LALPOF, Leucemie Aigu€e Lymphoblastique Paris-Ouest-France; LFS, leukemia-free survival; MDS, myelodysplastic syndromes; MMRD, mismatched related donor; MMUD,
mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; NILG, Northern Italy Leukemia Group; NR, not reported; Ph+, Philadelphia chromosome-positive; OS, overall survival;
RIC, reduced-intensity conditioning; SCT, stem cell transplantation; TRM, treatment-related mortality, UCBT, unrelated cord blood transplant; URD, unrelated donor.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
†Not significant: P > .05.
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Biol Blood Marrow Transplant 18:18-36, 2012 31The Role of Cytotoxic Therapy with Hematopoietic SCT
in the Treatment of ALLComparison of Induction Therapies
In a prospective, multicenter study Labar et al. [40]
reported no significant difference in 6-year EFS or
6-year OS between adult ALL patients randomized to
receive dexamethasone versus prednisolone as part of
their induction therapy prior to receiving further chemo-
therapy or undergoing allogeneic or autologous SCT.
Wassman et al. [41] reported no significant differ-
ence in 2-year OS between adult patients with Ph1
ALLwho received alternating or concurrent schedules
of chemotherapy and imatinib as induction therapy
prior to undergoing an allogeneic or autologous SCT.
Comparison of Reinduction versus No-
Reinduction Therapy for Refractory/Relapsed
ALL
A retrospective analysis of a prospective, single-
center treatment algorithm by Terwey et al. [42] found
that adult patients with refractory or relapsed ALL
who did not received reinduction chemotherapy prior
to allogeneic SCT (31% received prophylactic donor
lymphocytic infusions [DLI] starting after day 1 60)
had significantly better 5-year OS than patients who
did receive reinduction chemotherapy prior to alloge-
neic SCT (40% received prophylactic DLI).
Comparison of Conditioning Regimens
Marks et al. [43] reported no significant differences
in 3-year DFS or 3-year OS, and Kojima et al. [44] re-
ported no significant difference in 2-year OS, in com-
parisons of RIC versus myeloablative conditioning
prior to allogeneic SCT in adult ALL patients.
In a retrospective analysis of two prospective trials,
Deconinck et al. [45] reported significantly worse
4-year EFS and 4-year OS in patients who underwent
an intensified versus standard dose induction, consoli-
dation, and myeloablative conditioning regimen prior
to allogeneic SCT, primarily because of an increased
toxic death rate in the intensive protocol.NONCOMPARATIVE STUDIES OF
TRANSPLANTATION FOR ADULTALL
There were 14 noncomparative cohort studies
[46-59] published since the original EBR that
examined the use of SCT as therapy for adult ALL.
The design, methodology, and outcomes data from
these noncomparative studies are summarized in
Appendix B (online only). The studies represent non-
randomized single- or multi-institutional experiences
with various transplantation techniques or retrospec-
tive analyses of transplant registry data. The quality
of the noncomparative SCT studies ranged from 21
to 22. These noncomparative data on SCT for ALL
provide additional, though lower level evidence, onSCT for ALL and thus are cited to provide added per-
spective on the published data.AREAS OF NEEDED RESEARCH AND
ONGOING STUDIES
After reviewing the updated evidence on the use of
SCT for adult ALL, the expert panel identified several
important areas of needed research. Some of these
areas are being investigated by ongoing studies that
are currently accruing patients, maturing follow-up,
or which have been published in abstract form. The
areas of needed research are grouped by topic, num-
bered, and followed by a brief description of some rel-
evant ongoing studies, with some comment on their
potential contribution to future treatment decisions.
None of these studies were used as evidence for the re-
view or for making treatment recommendations. This
section is provided for the reader’s information only.Allogeneic SCT versus Chemotherapy
1. Reevaluate allogeneic SCT versus more inten-
sive chemotherapy regimens, especially in younger
(\35 years) adults, and in the context of biologic
therapies and Tyrosine Kinase Inhibitors (TKIs)
(for Ph1 ALL).
The ongoing studies summarized below follow
a biologic allocation and comparison based upon do-
nor availability in an attempt to perform a statistically
randomized study that avoids bias. Intent-to-treat,
donor versus no-donor comparisons avoid the bias of
assessing only those with a donor and who were con-
sidered medically suitable to proceed with SCT; how-
ever, they can still result in confounding because of
other types of SCT performed in those without
a matched related donor.
A meta-analysis by Pidala et al. [60] consisted of
aggregate outcome data from 14 trials and provided
a donor versus no-donor comparison in 3215 adult pa-
tients to determine whether or not there is a survival
benefit to allogeneic SCT for ALL in CR1.
Litzow et al. [61] presented theUKALLXII/E2993
trial on 1229 adult (14-65 years) Ph-negative B-ALL
patients who were randomized to autologous SCT or
to consolidation and maintenance chemotherapy.
Patients\55 years of age with a matched sibling donor
were biologically assigned to myeloablative allogeneic
SCT. Analyses included chemotherapy versus autolo-
gous SCT and donor versus no-donor comparisons.
Leguay et al. [62] reported the outcomes of 75
young adult (15-59) with Ph-negative ALL. Of the
70 patients who attained CR, 54 (77%) were consid-
ered high risk and eligible for allogeneic SCT. Of
these, 30 had a donor and received a SCT, and 24 re-
ceived intensification and maintenance chemotherapy
(donor/no-donor comparison). Of the remaining
32 Biol Blood Marrow Transplant 18:18-36, 2012D. M. Oliansky et al.16 patients in CR, two died before evaluation and 14
with low-risk ALL received chemotherapy alone fol-
lowed by maintenance therapy.
A clinical trial (NCT00792948) sponsored by the
Southwest Oncology Group is currently accruing pa-
tients to compare combination therapy (HyperCVAD1
dasatinib) with or without allogeneic SCT for patients
with Ph1 or BCR-ABL1 ALL. The estimated enroll-
ment is 85 patients, and the primary clinical outcomes
of interest are 1-year relapse-free survival andOS.This
trial will provide preliminary estimates of efficacy, but
future study of newer TKIs may yield better outcomes
or identify situations where one agent, dose, or sched-
ule is preferred.Allogeneic SCT versus Chemotherapy ± TKI
Therapy
2. Assess the ability of TKIs to reduce the leukemia
murden pre- or post-SCT in Ph1 ALL patients and
evaluate whether this can improve survival outcomes
after autologous and allogeneic. Study of different
TKIs, dose, and schedule will be important.
In a prospective, Northern Italy Leukemia Group
study, Rambaldi et al. [63] investigated the clinical out-
comes of adult Ph1 ALL patients who underwent
allogeneic SCT (n5 58) versus standard chemotherapy
(n 5 33), or autologous SCT (n 5 9) with or without
imatinib as part of induction/consolidation therapy.
Fielding et al. [64] reported the final results of the
UKALLXII/COG2993 trial, comparing the outcomes
of three nonrandomized subgroups of Ph1 ALL pa-
tients on imatinib versus no imatinib, early versus
late imatinib, and allogeneic SCT versus chemother-
apy maintenance including imatinib.
There are several ongoing clinical trials investigat-
ing SCT with or without TKI therapy. The Gruppo
ItalianoMalattieEmatologichedell’Adulto (GIMEMA)
is sponsoring a phase II trial (NCT00458848) compar-
ing the effectiveness of combination chemotherapy
with or without imatinib and/or peripheral blood SCT
for adult Ph1 ALL patients. The estimated enrollment
is 253 patients, and the primary outcomes of interest are
1-year DFS and OS.
The Group for Research in Adult Acute Lympho-
blastic Leukemia is sponsoring a randomized clinical
trial (NCT00327678) comparing standard versus inten-
sified induction for Ph-negative T or B ALL, rituximab
versus no rituximab with or without allogeneic SCT
for Ph-negative B ALL, and imatinib-based induction
versus chemotherapy plus imatinib induction with or
without allogeneic SCT based on donor availability
and minimal residual disease status after induction for
Ph1 ALL. The primary outcomes of interest are EFS
and OS and the percentage of patients with minimal re-
sidual disease after induction or consolidation therapy.
The estimated enrollment is 1080 patients.A clinical trial (NCT01256398) sponsored by the
Cancer and Leukemia Group B and the National Can-
cer Institute is investigating the use of dasatinib fol-
lowed by allogeneic or autologous SCT as treatment
for older ($50 years) adult patients with de novo Ph1
ALL. The estimated enrollment is 66 patients, and
the primary outcome measure is 3-year DFS.
The Sheba Medical Center is sponsoring a clinical
trial (NCT00750659) investigating the use of nilotinib
pre- and post-allogeneic SCT for adult Ph1 ALL or
advanced chronic myeloid leukemia patients. The esti-
mated enrollment is 24 patients, and the primary mea-
sures are safety and response at one year.
Minimal Residual Disease (MRD)
3. Improvement in the detection andmonitoring of
MRD during initial treatment to guide individual
patient eligibility and timing of allogeneic SCT.
In a Polish Adult Leukemia Group study (PALG
5-2007), Giebel et al. [65] compared the outcomes of
108 adult patientswithALLwho received an individual-
ized therapeutic approach with treatment intensity ad-
justed to MRD status and age, versus those from the
PALG4-2002 trial in which MRD status was not taken
into account for treatment decisions. In both studies,
patients with standard risk ALL received induction/
consolidation followed by maintenance, whereas those
with high-risk disease were referred for allogeneic SCT.
The Johann Wolfgang Goethe University Hospi-
tals clinical trial (NCT00198991) is a multicenter
study of treatment optimization in adult ALL based
on the risk of relapse and MRD status. The primary
outcomes measures are remission rate, remission
duration, DFS, and OS. Secondary measures include
realization of SCT, toxicity, and course of MRD.
The estimated enrollment is 1250 patients.
4. Monitoring of MRD after SCT to detect early
post-SCT relapse in need of preemptive therapy.
This may indicate patients at higher risk of early
recurrence, but effective therapy will also need to be
developed.
Tang et al. [66] retrospectively analyzed the MRD
status at day 1100 post-allogeneic SCT of 52 high-
risk adult patients with ALL (n 5 25; acute myeloge-
nous leukemia [AML], n 5 27) to evaluate the
prognostic value of MRD pre- and post-SCT.RIC for Allogeneic SCT
5. Indications for using RIC versus myeloablative
conditioning regimens for allogeneic SCT. The broad
range of conditioning intensity will need further study,
adjusted for a patient’s tolerance of conditioning toxic-
ity balanced against the risk of relapse. It is likely that
randomized comparative trials will be essential.
The Asan Medical Center is sponsoring a clinical
trial (NCT01037764) of adult patients with
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busulfan-fludarabine-antithymocyte globulin condi-
tioning regimens followed by BMT or peripheral
blood stem cell transplantation (PBSCT), respectively,
using HLA-matched sibling donors, HLA-matched
unrelated donors, or HLA-mismatched related do-
nors. Patients with anHLA-matched unrelated or mis-
matched related donor will receive the busulfan-
fludarabine-antithymocyte globulin conditioning and
PBSCT. The outcome measures of interest include
3-year relapse rate, LFS, treatment-related mortality
(TRM), and OS, and the estimated enrollment is 100
patients. Heterogeneity in patients, donor types, and
disease risk status may confound conclusions in this
modest sized trial.Cord Blood Transplantation
6. Evaluation of cord blood transplantation tech-
niques, such as single unit, double unit, and ex vivo
expansion, to improve survival outcomes and reduce
TRM. Larger multicenter experience will be needed
to more fully evaluate the broader applicability of
cord blood grafting for adults with ALL.
Brunstein et al. [67] investigated the effect of unre-
lated donor stem cell source on outcomes in adult ALL
(n 5 62) or AML (n 5 523) patients, comparing
PBSCT versus double cord blood transplantation after
an RIC regimen.
Rocha et al. [68] compared acute leukemia patients
(38% ALL, 62% AML) who underwent a double ver-
sus single cord blood transplantation in CR1, CR2, or
CR3. The clinical outcome of interest was 3-year LFS
and stratified by disease.Post-SCT Patient Status and Management
7. Assessment of patient quality of life and
functional status after successful SCT.
A clinical trial sponsored by the University Health
Network, Toronto (NCT01148927) is evaluating the
quality of life of long-term survivors of adult ALL
who were treated with a modified Dana Farber Cancer
Institute ALL protocol (91-01). Patients over 18, and
who have completed the protocol at least three months
prior and are in complete rmission are included.
The patients complete several well-validated question-
naires assessing various quality of life issues of concern
to these patients. Enrollment is estimated at 50
patients.
8. Assess the impact of management plans and
follow-up care to facilitate better quality of life for
ALL patients, regardless of treatment.
There are no ongoing studies specifically for ALL
that address this area of needed research.STRENGTHS/LIMITATIONS AND
DISCUSSION
The strengths of this updated systematic evidence-
based review are the details about each study’s design
and outcomes conveyed in the summary tables for
each major section, and the consensus treatment rec-
ommendations made by the adult ALL expert panel.
A limitation is the exclusion of nonpeer-reviewed
data. Unpublished data can represent ‘‘negative’’ find-
ings that could lead to publication bias; however, the
inclusion of high-quality, peer-reviewed publicly avail-
able data was of paramount importance. With the
exception of the Ongoing Studies section, data pub-
lished in abstract form were not included in this review
because of the inadequate details of study design or pa-
tient characteristics, making a true assessment of the
widespread applicability or impact of the treatment
outside the scope of the trial difficult.
The quality of this systematic EBR is affected by
treatment modalities that vary over time. Chemother-
apy regimens, HLA typing techniques, novel pre- and
post-SCT biologic and TKI therapies, and post-SCT
supportive care change considerably over the course
of these reviews and updates. The clinical research
process is lengthy, making data from many of these
studies outmoded by the time of publication. Much
of the new data presented in this updated EBR may
be obsolete in terms of the current standard of care,
stressing the need for more timely updates of the
EBRs. In addition, the lengthy process of conducting
and reporting clinical research emphasizes the need
to identify surrogate endpoints or molecular markers
that are predictive of long-term survival in adult
ALL patients. Further delineation of clinical risk
factors may facilitate appropriate selection of ALL
patients for SCT.ACKNOWLEDGMENTS
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in the Treatment of ALLAPPENDIX A: METHODOLOGY FOR THE
ADULTACUTE LYMPHOBLASTIC LEUKEMIA
EVIDENCE-BASED REVIEW UPDATE
Introduction
In 1999, the American Society for Blood and
Marrow Transplantation (ASBMT) began developing
systematic evidence-based reviews (EBR) and position
statements on the effectiveness of autologous and
allogeneic hematopoietic stem cell transplantation
(SCT) for specific diseases. The purpose of these
reviews is to provide evidence in support of clinical de-
cisions and matters of public policy regarding SCT
and achieve broader and more consistent coverage
from payers for established indications for SCT. The
ASBMT EBR Steering Committee developed specific
policies outlining the methodology to be followed
for these reviews [1,2]. Currently, eight reviews have
been published in Biology of Blood and Marrow
Transplantation (BBMT) on the use of SCT in the
therapy of: diffuse large B cell lymphoma [3], multiple
myeloma [4], pediatric acute lymphoblastic leukemia
(ALL) [5], adult ALL [6], pediatric acute myeloid
leukemia (AML) [7], adult AML [8], myelodysplastic
syndromes [9], and follicular lymphoma [10].
In 2009, theASBMTEBRSteeringCommittee de-
termined that previously published reviews should be
updated regularly at approximately 5-year intervals.
The purpose of the updates is to provide a summary
of recent clinical evidence, provide timely treatment
recommendations, and determine if new evidence
strengthens or changes the treatment recommenda-Appendix A, Table 1. Grading the Quality of Design and Strengt
Levels of Evidence
1++ High quality meta-analyses, systematic reviews of randomized c
1+ Well conducted meta-analyses, systematic reviews of RCTs, or
12 Meta-analyses, systematic reviews of RCTs, or RCTs with a hig
++ High-quality systematic reviews of case-control or cohort stud
High-quality case-control or cohort studies with a very low risk
causal
2+ Well-conducted case control or cohort studies with a low risk
relationship is causal
22 Case-control or cohort studies with a high risk of confounding
3 Nonanalytic studies (eg, case reports, case series)
4 Expert opinion
Reprinted with permission from Harbour R, Miller J. A new system for
2001;323:334-336.
Appendix A, Table 2. Grading the Strength of the Treatment Re
Grades of Recommendation
A At least 1 meta-analysis, systematic review, or randomized con
population; or a systematic review of RCTs or a body of evi
target population, and demonstrating overall consistency of
B A body of evidence including studies rated as 2++, directly app
results; or extrapolated evidence from studies rated as 1++
C A body of evidence including studies rated as 2+, directly applica
or extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or extrapolated evidence from studies ra
Reprinted with permission from Harbour R, Miller J. A new system for
2001;323:334-336.tions provided in original EBR. By providing these up-
dates, physicians will have access to timely information
that will facilitate and help disseminate advances in the
field of transplantation. To guide its own activities and
that of the expert panel associated with each review, the
ASBMT EBR Steering Committee developed a policy
statement specifying the methodology to be followed
for updating each review [11]. The same expert panel
members associated with the original EBR are invited
to participate in the update process as well. The diffuse
large B cell lymphoma update was the first to be pub-
lished [12], and the adult and pediatric ALL updates
are the next in the series, as requested by the ASBMT.Expert Panel Selection for EBR Update
To achieve an appropriate balance, physicians who
have extensive clinical experience and published re-
search studies using SCT and other therapies in the
treatment of the specific disease of interest are invited
to join an independent expert panel that examines the
summarized literature and provides subsequent treat-
ment recommendations based on the available evidence.
Potential panelists are restricted to U.S.-based institu-
tions for two reasons: (1) ease of logistics in convening
teleconferences, and (2) differences in thehealthcare sys-
tems and health insurance coverage between the United
States and other countries (including Canada, Europe,
etc), which may result in different expert recommenda-
tions based on considerations of costs and access to care.
In addition to clinical and research physicians, at least
one third-party payer representative, a patient advocate,h of Evidence
ontrolled trials (RCTs), or RCTs with a very low risk of bias
RCTs with a low risk of bias
h risk of bias
ies
of confounding, bias, or chance, and a high probability that the relationship is
of confounding, bias, or chance, and a moderate probability that the
, bias, or chance, and a significant risk that the relationship is not causal
grading recommendations in evidence-based guidelines. Br Med J.
commendation
trolled trial (RCT) rated as 1++, and directly applicable to the target
dence consisting principally of studies rated as 1+, directly applicable to the
results
licable to the target population, and demonstrating overall consistency of
or 1+
ble to the target population and demonstrating overall consistency of results;
ted as 2+
grading recommendations in evidence-based guidelines. Br Med J.
36.e2 Biol Blood Marrow Transplant 18:18-36, 2012D. M. Oliansky et al.and a liaison to the ASBMTSteeringCommittee are in-
vited to serve on the panel.
Literature SearchMethodology for the Adult All
EBR Update
The SCOPUS database, which includes PubMed
and Medline, the Websites developed by the National
Center of Biotechnology Information at the National
Library of Medicine of the National Institutes of
Health, were first searched on July 29, 2010, using
the search terms ‘‘acute lymphoblastic leukemia’’ OR
‘‘ALL’’ AND ‘‘transplant’’ limited to ‘‘human trials,’’
‘‘English language,’’ and a publication date of January
1, 2005 or later. An updated search was conducted on
October 15, 2010. In addition to the online database
searches, a manual search of the reference lists of the
included articles and relevant reviews published since
January 2005 was conducted.
Papers that were published before January 2005,
included fewer than 25 ALL patients, or were not
peer-reviewed were excluded. Also excluded were edi-
torials, letters to the editor, Phase I (dose escalation or
dose finding) studies, reviews, consensus conference
papers, practice guidelines, and laboratory studies
with no clinical correlates. Abstracts and presentations
at national or international meetings were not used for
the treatment recommendations in this update for rea-
sons previously described [5]. However, abstracts are
included in the ‘‘Areas of Needed Research and Ongo-
ing Studies’’ section for the reader’s information.
Several of the studies evaluated for inclusion in this
adult ALL update included patients with AML; there-
fore, to be included, at least 65% of a study’s patients
had to have ALL, unless the results were stratified by
disease.
Qualitative and Quantitative Grading of the
Evidence
The hierarchy of evidence, including a grading
system for the quality and strength of the evidence and
strength of each treatment recommendation, was pub-
lished as an editorial policy statement in BBMT in
2005 [2]. Appendix A, Tables 1 and 2, reprinted from
the policy statement, define criteria used to grade the
studies that were included in this update and criteria to
grade the treatment recommendations, respectively.
Study design, including sample size, patient selection
criteria, duration of follow-up, and treatment protocol
also were considered in evaluating the studies. Clinical
studies are described in the tables with sufficient detail
to give a concise summary of study design and patient
outcomes.
All data in the text and tables were abstracted from
the original manuscripts by the first author (D.O.) and
double checked for accuracy and clarity by 2 other
authors (T.H. and P.L.M.). Some articles containedinconsistencies within the data reported; the data
most consistent with the text of the article were in-
cluded in this review.
Format of the Adult All EBR Update
Evidence is taken from studies published after
January 2005 of adult ALL patients. For each section
of the review, a summary paragraph provides an overall
description of the number and types of studies in-
cluded as evidence, as well as a brief synopsis of
outcomes. As noted earlier, unlike the original ALL
EBRs, in which each article was summarized in detail
in the text, this update presents the study design,
patient population, and clinical outcomes only in the
detailed summary tables.
The highest quality studies are presented in the
tables first, while studies of equal quality are pre-
sented in descending order by study population size.
Individual studies that were also included in a meta-
analysis are identified in the tables. New evidence is
provided first in each table, followed by the highest
quality studies (ratings from 111 to 211) used to
make treatment recommendations in the original
adult ALL EBR. Both Level 1 and Level 2 evidence
is presented in the tables for each study that provided
biologic assignment (donor versus no donor) and
randomized (autologous SCT versus chemotherapy)
results. When specific data elements of a study’s
patient population or disease characteristics were
not included in a table, it was because the information
was not provided in the article.
Consensus Process for Treatment
Recommendations
The Treatment Recommendations Table (Table 1
in the Adult ALL EBR Update) contains the summary
of consensus treatment recommendations made by the
expert panel based on the summarized evidence. The
consensus process involves a teleconference during
which panelists critically discuss the evidence for
each section of the review and develop initial treatment
recommendations according to the categories in
Appendix A, Table 2. The information is summarized
by the primary authors in the Treatment Recommen-
dations Table and distributed to the panelists for addi-
tional review and clarification. Any changes suggested
by an individual panelist are circulated for review and
approval by all panelists. This iterative process con-
cludes when a final version of the Treatment Recom-
mendations Table is approved by all panelists.
After the final draft of the Adult ALL EBR Update
is approved by the expert panel it is reviewed by the
ASBMT EBR Steering Committee and then submit-
ted to the BBMT journal for peer-review. Any changes
requested during the peer-review process must be re-
viewed and approved by all the expert panelists.
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Appendix B. Noncomparative Studies of Transplantation for Adult ALL
Reference and Patient
Populations
Quality/
Strength
of Evidence* Treatment Regimen
Sample
Size
Age, Years Median Follow-Up (in Months) %
Median Duration % % T % EFS/DFS/ % OS
(Range) CR1 (Months) Ph+ Lineage Med (Range) TRM LFS (95% CI) (95%CI)
RELATEDALLOGENEIC SCT
[46] Huang 2009 2+ Total ALL 142 25 (2-56) NR 13% 9% NR 5-year 3-year LFS NR
2001-2007 Overall 30% 55.9% ± 5%
Retrospective, Single Ctr Unmanipulated ALL ALL
Total n 5 250 Mismatched/
57% ALL (stratified) Haploidentical RD Allo
(others AML)
61.3% ALL in CR
[47] Fouillard 2008 2+ Total ALL 53 36 (16-68) NR 13% NR 60 (1-275) 3% 1-year LFS NR
1975-2003 Overall 52% ± 10%
Retrospective, Registry Syngeneic identical ALL
EBMT twin SCT
Total n 5 162
33% ALL (stratified)
(others AML)
Overall 72% in CR1
UNRELATEDALLOGENEIC SCT
[48] Marks 2008 2+ Total 169 33 (16-59) NA 0% 19% 54 (NR) 5-year NR 5-year OS
1995-2004 42% 39%
Retrospective, Registry MUD or MMUD Allo
CIMBTR
Ph-negative ALL in CR1
RELATED OR UNRELATED ALLOGENEIC SCT
[49] Hamaki 2005 2++ Total 33 55 (17-68) NR 30% 3% 11.6 (4-37) 27% 1-year RFS 1-year OS
2000-2003 29.8% 39.6%
Retrospective, Multictr RIC prior to
ALL (39% in CR1) MRD, MMRD, or
18% previous SCT MUD Allo SCT
[50] Duval 2010 2+ Total ALL 582 29 (<1-60) 8 (<1-97) NR NR 61 (2-137) 100 day NR 3-year OS
1995-2004 ALL ALL Overall 41% 16% (13%-20%)
Retrospective, Registry MSD, MRD, MUD,
CIBMTR or MMUD Allo SCT
ALL Refractory/Relapse
Total n 5 2255
26% ALL (stratified)
(Continued )
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Appendix B. (Continued )
Reference and Patient
Populations
Quality/
Strength
of Evidence* Treatment Regimen
Sample
Size
Age, Years Median Follow-Up (in Months) %
Median Duration % % T % EFS/DFS/ % OS
(Range) CR1 (Months) Ph+ Lineage Med (Range) TRM LFS (95% CI) (95%CI)
[51] Yanada 2005 2+ Total 197 37 (16-59) NR 100% NR 57.6 (NR) NR NR 5-year OS
1991-2001 22%
Retrospective, Registry TBI regimen (84%) prior
JSHCT to MSD, MMRD, MUD,
Ph+ ALL (57% in CR) or MMUD Allo SCT
[52] Mohty 2008 2+ Total 97 38 (17-65) NR 38% NR 33.6 (5-76) NRM 2-year LFS 2-year OS
1996-2004 28% 21% ± 4% 31% ± 5%
Retrospective, Registry RIC prior to
EBMT MSD or MUD Allo SCT
ALL (29% in CR1)
35% previous SCT
[53] Shigematsu 2008 2+ Total 37 26 (15-58) NR 32.3% 10.8% 35.1 (.9-163) 5.4% NR 3-year OS
1993-2007 89.2%
Retrospective, Single Ctr Medium-dose VP16 + Cy
ALL (94.6% in CR1) + TBI prior to MRD,
MUD, or MMUD
[54] Kebriaei 2006 2+ Total 35 30 (15-55) NR 32% 0% 21 (3-46) 2-year 2-year PFS 2-year OS
1999-2004 24% 30% (15%-46%) 47% (28%-63%)
Prospective, Single Ctr Cy + TBI + Rituximab
ALL (26% in CR1) prior to MSD or MUD
Allo SCT
[55] Gutierrez 2007 22 Total 43 19 (1-55) NR NR NR 7.8 (1-35) 21% NR 3-year OS
No study dates reported 31%
+Prospective, Multicenter RIC prior to
ALL in CR2 MSD Allo SCT
63% > 16 years
ALLOGENEIC OR AUTOLOGOUS SCT
[56] Song 2007 2+ Total 34 26 (18-56) NA NR NR 51 (13-142) NR 4-year EFS 4-year OS
1987-2005 29 SCT 68% 72%
Retrospective, Registry (ITT) (ITT)
BMT Program of BC MSD Allo SCT (4) or
and BCCA Database Auto SCT (25)
T-lineage ALL
(94% in CR1)
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Appendix B. (Continued )
Reference and Patient
Populations
Quality/
Strength
of Evidence* Treatment Regimen
Sample
Size
Age, Years Median Follow-Up (in Months) %
Median Duration % % T % EFS/DFS/ % OS
(Range) CR1 (Months) Ph+ Lineage Med (Range) TRM LFS (95% CI) (95%CI)
[57] Kantarjian 2010 22 Total 172 32 (16-81) $12 months 16% NR NR NR NR 3-year OS
1990 - NR 46 SCT 25% 25%
Retrospective, Single Ctr MSD or MUD Allo (44) (SCT patients only)
ALL in $CR2 or Auto SCT (2)
[58] Dudler 2009 22 Total 42 43 (17-67) NR 29% 19% 55 (4-136) 21% 5-year DFS 5-year OS
1995-2005 31 SCT 16% ± 13% 23% ± 15%
Retrospective, 2 Centers DV-ICE intensive (ITT) (ITT)
ALL (76% in CR1) induction, then immediate
MSD, MUD, MMRD
Allo SCT (24) or
Auto SCT (7)
based on donor availability
POST-SCT IMATINIB FOR MRD
+
PH
+
ALL
[59] Wassmann 2005 22 Total 27 48 (16-63) NR 100% NR 15.6 (2-31) na PFS NR
Study dates NR MRD responders 14 68% ± 21% 12 months
Prospective, Multicenter MRD nonresponders 13 8% ± 7% 13 months
MRD
+
Ph
+
ALL Allo (24) or Auto (3) SCT
ALL indicates acute lymphoblastic leukemia; Allo, allogeneic; AML, acute myeloid leukemia; Auto, autologous; BC, British Columbia; BCCA, British Columbia Cancer Agency; BMT, bone marrow transplantation; CI,
confidence interval; CIBMTR, Center for International Blood and Marrow Transplant Research; CML, chronic myeloid leukemia; CR, complete remission; Cy, cyclophosphamide; DFS, disease-free survival; DV-ICE,
dexamethasone/vincristine-idarubicine/cytosine-arabinoside/etoposide; EBMT, European Group for Blood and Marrow Transplant; EFS, event-free survival; HR, high risk; ITT, intention-to-treat; JSHCT, Japan Society
of Hematopoietic Cell Transplantation; LFS, leukemia-free survival; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor or minimal residual disease; MSD, matched
sibling donor; MUD, matched unrelated donor; NR, not reported; OS, overall survival; PFS, progression-free survival; Ph+, Philadelphia chromosome-positive; RD, related donor; RIC, reduced-intensity conditioning;
RD, related donor; SCT, stem cell transplantation; TBI, total-body irradiation; TRM, treatment-related mortality; VP16, etoposide.
*Quality and strength of evidence definitions are listed in Appendix A, Table 1.
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